Influence of psychotherapy attendance on buprenorphine treatment outcome

Iván D. Montoya, Jennifer R. Schroeder, Kenzie L. Preston, Lino Covi, Annie Umbricht, Carlo Contoreggi, Paul J. Fudala, Rolley E. Johnson, David A. Gorelick

Research output: Contribution to journalArticle

Abstract

We evaluated the influence of psychotherapy attendance on treatment outcome in 90 dually (cocaine and heroin) dependent outpatients who completed 70 days of a controlled clinical trial of sublingual buprenorphine (16 mg, 8 mg, or 2 mg daily, or 16 mg every other day) plus weekly individual standardized interpersonal cognitive psychotherapy. Treatment outcome was evaluated by quantitative urine benzoylecgonine (BZE) and morphine levels (log-transformed), performed three times per week. Repeated-measures linear regression was used to assess the effects of psychotherapy attendance (percent of visits kept), medication group, and study week on urine drug metabolite levels. Mean psychotherapy attendance was 71% of scheduled visits. Higher psychotherapy attendance was associated with lower urine BZE levels, and this association grew more pronounced as the study progressed (p = 0.04). The inverse relationship between psychotherapy attendance and urine morphine levels varied by medication group, being most pronounced for subjects receiving 16 mg every other day (p = 0.02). These results suggest that psychotherapy can improve the outcome of buprenorphine maintenance treatment for patients with dual (cocaine and opioid) dependence.

Original languageEnglish (US)
Pages (from-to)247-254
Number of pages8
JournalJournal of Substance Abuse Treatment
Volume28
Issue number3
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Buprenorphine
Psychotherapy
Urine
Morphine
Cocaine-Related Disorders
Heroin
Controlled Clinical Trials
Cognitive Therapy
Cocaine
Opioid Analgesics
Linear Models
Outpatients
Pharmaceutical Preparations

Keywords

  • Buprenorphine
  • Cocaine
  • Dual dependence
  • Heroin
  • Psychotherapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Montoya, I. D., Schroeder, J. R., Preston, K. L., Covi, L., Umbricht, A., Contoreggi, C., ... Gorelick, D. A. (2005). Influence of psychotherapy attendance on buprenorphine treatment outcome. Journal of Substance Abuse Treatment, 28(3), 247-254. https://doi.org/10.1016/j.jsat.2005.01.004

Influence of psychotherapy attendance on buprenorphine treatment outcome. / Montoya, Iván D.; Schroeder, Jennifer R.; Preston, Kenzie L.; Covi, Lino; Umbricht, Annie; Contoreggi, Carlo; Fudala, Paul J.; Johnson, Rolley E.; Gorelick, David A.

In: Journal of Substance Abuse Treatment, Vol. 28, No. 3, 04.2005, p. 247-254.

Research output: Contribution to journalArticle

Montoya, ID, Schroeder, JR, Preston, KL, Covi, L, Umbricht, A, Contoreggi, C, Fudala, PJ, Johnson, RE & Gorelick, DA 2005, 'Influence of psychotherapy attendance on buprenorphine treatment outcome', Journal of Substance Abuse Treatment, vol. 28, no. 3, pp. 247-254. https://doi.org/10.1016/j.jsat.2005.01.004
Montoya, Iván D. ; Schroeder, Jennifer R. ; Preston, Kenzie L. ; Covi, Lino ; Umbricht, Annie ; Contoreggi, Carlo ; Fudala, Paul J. ; Johnson, Rolley E. ; Gorelick, David A. / Influence of psychotherapy attendance on buprenorphine treatment outcome. In: Journal of Substance Abuse Treatment. 2005 ; Vol. 28, No. 3. pp. 247-254.
@article{1683b17ae96841829dc0de40977ab78e,
title = "Influence of psychotherapy attendance on buprenorphine treatment outcome",
abstract = "We evaluated the influence of psychotherapy attendance on treatment outcome in 90 dually (cocaine and heroin) dependent outpatients who completed 70 days of a controlled clinical trial of sublingual buprenorphine (16 mg, 8 mg, or 2 mg daily, or 16 mg every other day) plus weekly individual standardized interpersonal cognitive psychotherapy. Treatment outcome was evaluated by quantitative urine benzoylecgonine (BZE) and morphine levels (log-transformed), performed three times per week. Repeated-measures linear regression was used to assess the effects of psychotherapy attendance (percent of visits kept), medication group, and study week on urine drug metabolite levels. Mean psychotherapy attendance was 71{\%} of scheduled visits. Higher psychotherapy attendance was associated with lower urine BZE levels, and this association grew more pronounced as the study progressed (p = 0.04). The inverse relationship between psychotherapy attendance and urine morphine levels varied by medication group, being most pronounced for subjects receiving 16 mg every other day (p = 0.02). These results suggest that psychotherapy can improve the outcome of buprenorphine maintenance treatment for patients with dual (cocaine and opioid) dependence.",
keywords = "Buprenorphine, Cocaine, Dual dependence, Heroin, Psychotherapy",
author = "Montoya, {Iv{\'a}n D.} and Schroeder, {Jennifer R.} and Preston, {Kenzie L.} and Lino Covi and Annie Umbricht and Carlo Contoreggi and Fudala, {Paul J.} and Johnson, {Rolley E.} and Gorelick, {David A.}",
year = "2005",
month = "4",
doi = "10.1016/j.jsat.2005.01.004",
language = "English (US)",
volume = "28",
pages = "247--254",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Influence of psychotherapy attendance on buprenorphine treatment outcome

AU - Montoya, Iván D.

AU - Schroeder, Jennifer R.

AU - Preston, Kenzie L.

AU - Covi, Lino

AU - Umbricht, Annie

AU - Contoreggi, Carlo

AU - Fudala, Paul J.

AU - Johnson, Rolley E.

AU - Gorelick, David A.

PY - 2005/4

Y1 - 2005/4

N2 - We evaluated the influence of psychotherapy attendance on treatment outcome in 90 dually (cocaine and heroin) dependent outpatients who completed 70 days of a controlled clinical trial of sublingual buprenorphine (16 mg, 8 mg, or 2 mg daily, or 16 mg every other day) plus weekly individual standardized interpersonal cognitive psychotherapy. Treatment outcome was evaluated by quantitative urine benzoylecgonine (BZE) and morphine levels (log-transformed), performed three times per week. Repeated-measures linear regression was used to assess the effects of psychotherapy attendance (percent of visits kept), medication group, and study week on urine drug metabolite levels. Mean psychotherapy attendance was 71% of scheduled visits. Higher psychotherapy attendance was associated with lower urine BZE levels, and this association grew more pronounced as the study progressed (p = 0.04). The inverse relationship between psychotherapy attendance and urine morphine levels varied by medication group, being most pronounced for subjects receiving 16 mg every other day (p = 0.02). These results suggest that psychotherapy can improve the outcome of buprenorphine maintenance treatment for patients with dual (cocaine and opioid) dependence.

AB - We evaluated the influence of psychotherapy attendance on treatment outcome in 90 dually (cocaine and heroin) dependent outpatients who completed 70 days of a controlled clinical trial of sublingual buprenorphine (16 mg, 8 mg, or 2 mg daily, or 16 mg every other day) plus weekly individual standardized interpersonal cognitive psychotherapy. Treatment outcome was evaluated by quantitative urine benzoylecgonine (BZE) and morphine levels (log-transformed), performed three times per week. Repeated-measures linear regression was used to assess the effects of psychotherapy attendance (percent of visits kept), medication group, and study week on urine drug metabolite levels. Mean psychotherapy attendance was 71% of scheduled visits. Higher psychotherapy attendance was associated with lower urine BZE levels, and this association grew more pronounced as the study progressed (p = 0.04). The inverse relationship between psychotherapy attendance and urine morphine levels varied by medication group, being most pronounced for subjects receiving 16 mg every other day (p = 0.02). These results suggest that psychotherapy can improve the outcome of buprenorphine maintenance treatment for patients with dual (cocaine and opioid) dependence.

KW - Buprenorphine

KW - Cocaine

KW - Dual dependence

KW - Heroin

KW - Psychotherapy

UR - http://www.scopus.com/inward/record.url?scp=17844392070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844392070&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2005.01.004

DO - 10.1016/j.jsat.2005.01.004

M3 - Article

C2 - 15857725

AN - SCOPUS:17844392070

VL - 28

SP - 247

EP - 254

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 3

ER -